Novel Drug Modalities

Supporting the Future of Therapeutics: Novel Drug Modalities

At Axela Biosciences, we provide high-quality support for various drug modalities, including small molecules, antibodies/ADCs, peptides, protein degraders (PROTACs, molecular glues, etc.), cell therapy (CAR-T, CAR-NK), gene therapy (gene-editing), mRNA therapies, RNA interference (RNAi), and nanoparticle-based therapies, etc. Our deep expertise, highly sensitive assay platforms, and ready-to-use reagents enable smarter, faster, and more predictive preclinical and translational insights—accelerating your path from discovery to development.

Partial sample studies listed

Antibody-Drug Conjugates (ADCs):
  • Internalization and trafficking studies
  • Target binding and specificity
  • Cytotoxicity and efficacy assays
  • Biomarker profiling and mechanism-of-action studies
Peptides:
  • Peptide stability in plasma, serum, and simulated GI fluids
  • Permeability and uptake studies across epithelial barriers
  • Receptor binding, signaling, and activity assays
  • Cell viability, apoptosis, and functional response readouts
  • In vivo-like potency and half-life prediction assays
  • Immunogenicity risk profiling
Targeted Protein Degraders (TPDs):

We provide tailored assay platforms for:

  • Screening degrader libraries
  • Monitoring target degradation kinetics
  • Evaluating selectivity and cellular context
  • Exploring downstream signaling and phenotypic outcomes
Cell Therapy:
  • Phenotypic characterization of immune and stem cell populations
  • Cytokine release profiling and immune activation assays
  • Cell viability, proliferation, and apoptosis analysis
  • Cytotoxicity and target cell killing assays (e.g., tumor cell lysis)
  • Transduction efficiency and expression verification
  • T cell exhaustion and memory marker profiling
  • Host immune response and cytokine storm risk assessment
  • Multiplex gene and protein expression analysis
  • In vitro potency assays aligned with intended MoA
  • Custom assay development tailored to specific cell products
Gene Therapy:

Directly profile 800 genes across 40 pathways
Study processes known to impact gene therapy development and manufacturing
• Cell State
• Host-Vector Interactions
• Innate Immune Response
• Systemic Immunity
• Toxicity